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a  b  s  t  r  a  c  t
Background: Human bone marrow transplantation (BMT) becomes an accepted treatment of
leukemia, aplastic anemia, immunodeﬁciency syndromes, and hematologic malignancies.
Colorectal surgeons must know how to determine and manage the main colonic complica-
tions.
Objective: To review the clinical features, clinical and pathological staging of graft vs host
disease (GVHD), and treatment of patients suffering with colonic complications of human
bone marrow transplantation.
Patients and methods: We  have reviewed the records of all patients that received an allogeneic
bone marrow transplant and were evaluated at our Colon and Rectal Surgery department
due  to gastrointestinal symptoms, between January 2007 and January 2012. The study was
carried out in patients who developed colonic complications, all of them with clinical,
histopathological or laboratory diagnosis.
Results: The study group was constituted by 77 patients, 43 male and 34 female patients. We
identiﬁed colonic complications in 30 patients (38.9%); ﬁve patients developed intestinal
toxicity due to pretransplant chemotherapy (6.4%); graft vs. host disease was present in
16  patients (20%); 13 patients (16.8%) developed acute colonic GVHD, and 3 (3.8%) chronic
GVHD. Infection was identiﬁed in 9 patients (11.6%).
Conclusions: The three principal colonic complications are the chemotherapy toxicity, GVHD,
and  superinfection; the onset of symptoms could help to suspect the type of complication
(0–20 day chemotherapy toxicity, 20 and more GVHD), and infection could appear in any
time of transplantation.©  2014 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. All
rights reserved.
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Complicac¸ões do  cólon  após  transplante  de  medula  óssea  humana
Palavras-chave:
Complicac¸ões do colo
Transplante de medula óssea
humana
Superinfecc¸ão
r  e  s  u  m  o
Experiência: O transplante de medula óssea humana (MOH) passou a ser um tratamento
adotado para leucemia, anemia aplástica, síndromes de imunodeﬁciência e neoplasias
hematológicas. Cirurgiões colorretais devem saber como determinar e tratar as principais
complicac¸ões  do cólon.
Objetivo: Revisar as características clínicas, estadiamentos clínico e patológico da doenc¸a
do  enxerto versus hospedeiro (DEVH) e o tratamento de pacientes padecendo com as
complicac¸ões  colônicas do transplante de medula óssea humana.
Pacientes e Métodos: Revisamos os registros de todos os pacientes que receberam um trans-
plante de medula óssea alogênica e foram avaliados em nosso Departamento de Cirurgia
do  Cólon e Reto em func¸ão de sintomas gastrointestinais, entre janeiro de 2007 e janeiro de
2012.  O estudo teve por base os pacientes que desenvolveram complicac¸ões do cólon, todos
com  diagnóstico clínico, histopatológico ou laboratorial.
Resultados: O grupo de estudo foi constituído por 77 pacientes, sendo 43 homens e 34
mulheres. Identiﬁcamos complicac¸ões do cólon em 30 pacientes (38,9%); cinco pacientes
exibiam toxicidade intestinal por quimioterapia antes do transplante (6,4%); DEVH estava
presente em 16 pacientes (20%), 13 pacientes (16,8%) foram acometidos por DEVH colônica
aguda três pacientes (3,8%) DEVH crônica. Infecc¸ão foi detectada em 9 pacientes (11,6%).
Conclusões: As três principais complicac¸ões do cólon são: toxicidade por quimioterapia,
DEVH e superinfecc¸ão. O surgimento dos sintomas poderia ajudar a levantar suspeitas sobre
o  tipo de complicac¸ão (0–20 dias, toxicidade por quimioterapia; 20 ou mais dias, DEVH).
Infecc¸ões  podem ocorrer em qualquer momento do transplante.
©  2014 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda.


























uring the 1980s the human bone marrow transplanta-
ion (BMT) became from experimental therapy for end-stage
atients to its current place as an accepted treatment of
eukemia, aplastic anemia, immunodeﬁciency syndromes,
nd hematologic malignancies.1–5 The long-term disease-free
urvival for untransfused patients with severe aplastic ane-
ia  is up to 80% and for patients with acute nonlymphoblastic
eukemia transplanted in ﬁrst remission it approaches 60%,1,2
herefore the number of allogeneic bone marrow transplanta-
ions performed worldwide increases exponentially.6,7
BMT  may cause intestinal damage by three mechanisms:
oxicity from pretransplant chemoradiation, graft-versus-host
isease (GVHD), and infection in the immunosuppressed
ost. The main late complication of allogeneic bone marrow
ransplant is the GVHD.3–5 Intestine, skin, lungs,8 liver and
ymphoid organs are the main target organs in GVHD.4 About
0–50% of allogeneic marrow recipients will develop intestinal
VHD,2,9–12 with a fatal outcome in up to 15%.11 Gastroin-
estinal tract involvement is frequently the most severe and
ifﬁcult to treat.4
Allogeneic bone marrow transplantation is now widely
racticed, and therefore, specialist evaluations for a mul-
idisciplinary team are now demanding; gastroenterologists
nd colorectal surgeons must know how to determine and
anage these main colonic complications. The aim of
his study is review the clinical, laboratorial, endoscopicand pathological features, and treatment of patients suf-
fering with colonic complications of human bone marrow
transplantation.
Patients  and  methods
We  have reviewed the records of all patients that received
an allogeneic bone marrow transplant and were evaluated at
our Colon and Rectal Surgery department due to gastrointesti-
nal symptoms, between January 2007 and January 2012. The
study was conducted only in patients who developed colonic
complications, all of them with clinical, histopathological or
laboratory diagnosis.
All patients were studied and admitted by the Hemato-
logy department and Bone Marrow Transplant Clinic due to
variable hematological diseases; they were evaluated by his-
tocompatibility typing to select a suitable marrow donor using
peripheral blood leukocytes to deﬁne the loci of the human
leukocyte antigen (HLA) complex, and received a prepara-
tive regimen for transplantation with busulfan (16 mg per
kilogram) q.i.d, over a 4 day period, plus cyclophosphamide
(120 mg  per kilogram) single dose, over a 2 day period, (BUCY 2
regimen) to eradicate malignant cells as well as prevent rejec-
tion of the donor marrow. The patients were placed in laminar
air-ﬂow isolation room, and all of them received prophylac-
tic therapy with methotrexate and cyclosporine to modulate
acute GVHD. A day after the preparative regimen that the
patients underwent for marrow infusions was “day zero” from
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Fig. 1 – Normal appearance of the colonic mucosa in
Fig. 2 – A rectal biopsy showing diffuse destruction of
regeneration at day 16–20, no pathogens were isolated fromcolonoscopy.
which all subsequent events were dated, as well as the onset
of digestive symptoms.
Results
The ﬁrst BMT  done in our hospital was in 1995, and its appli-
cation has been increasing with time. We reviewed the records
of 77 patients with allogeneic transplants performed between
2007 and 2012, who  presented digestive symptoms, and were
submitted to evaluation at the Colon and Rectal Surgery
department. The study group was constituted by 43 male and
34 female patients, with ages from 16 to 50 years, mean 31.3.
The indication for transplant was: in 38 patients Chronic Mye-
locytic Leukemia, in 20 patients Acute Myelogenous Leukemia,
in 8 patients Acute Lymphoblastic Leukemia, in 7 patients
Myelodisplasic Syndrome, and in 4 patients Aplastic Anemia.
Fig. 3 – Patchy erythema and inﬂamcrypts as effect of conditioning chemotherapy.
HLA was 100% identical in 65 patients. We  identiﬁed colonic
complications in 30 patients (38.9%) that are presented as fol-
lows.
Chemotherapy  toxicity
Five patients developed intestinal toxicity due to pretrans-
plant chemotherapy (6.4%); all of them presented high watery
diarrhea, anorexia, nausea, and crampy abdominal pain. The
symptoms onset was from day 5 to day 12. At physical
examination with generalized colic abdominal pain, there
was  increase in frequency of intestinal peristalsis but no
signs of peritonitis, colonic mucosa appeared normal in the
endoscopic studies (colonoscopy or rectoscopy) and biop-
sies reported only chemotherapy toxicity (Figs. 1 and 2) withstools. All patients were treated conservatively with ﬂuid
and electrolyte replacement and prophylactic therapy with
metronidazole 500 mg  IV t.i.d plus ciproﬂoxacin 500 mg  IV
mation of the colonic mucosa.
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Fig. 4 – Colonic biopsy showing apoptosis (cell necrosis in



































Fig. 5 – Colonoscopic appearance of CMV  infection. Ulcers
vary from punctuate lesions to coalescing deep ulcers.enudation.
.i.d. Resolution of the symptoms was achieved in 2–3 weeks
pproximately.
raft  vs.  host  disease
raft vs. host disease was present in 16 patients (20%), 13
atients (16.8%) developed acute colonic GVHD, and 3 (3.8%)
hronic GVHD; symptoms were developed from day 20 to
ay 182, characterized by nausea, anorexia, vomiting, crampy
bdominal pain, profuse diarrhea with mucous, and occa-
ionally lower gastrointestinal (GI) bleeding, with abdominal
istension without peritoneal signs.
4 patients developed skin (maculopapular skin rash on
he trunk, palms, soles and ears) and hepatic manifesta-
ions (jaundice and serum transaminase increase). All patients
nderwent colonoscopy with ﬁndings of patchy erythema
nd inﬂammation of the mucosa through the colon (Fig. 3),
ost frequently in ascendant colon, and ileocecal valve area;
istopathology study of the mucosal biopsies conﬁrmed GVHD
Fig. 4). All patients were treated with ﬂuid, an electrolyte
eplacement, and steroid therapy was initiated with metil-
rednisolone 0.5–2 mg/kg/day in all patients; 2 patients with
ower GI bleeding received subcutaneous injection of somato-
tatin analogs (octreotide, 50 g t.i.d), and 8 of the patients
ith acute GVHD received total parental nutrition (TPN) to
aintain intestinal rest. Bleeding stopped spontaneously in
ll patients. Eight patients received as a complement of their
ystemic immunosuppresion an empiric treatment with 9 mg
ral budesonide in a daily single dose for 3 weeks. One patient
eveloped acute respiratory failure and pulmonary hemor-
hage secondary to pulmonary GVHD and died on the 59th
osttransplant day.
The 3 patients with chronic GVHD were treated on an out-
atient basis with oral prednisone.nfection
nfection was identiﬁed in 9 patients (11.6%). 5 patients
ith cytomegaloviral enterocolitis (CMV) corroboratedby endoscopic appearance and histopathological studies
(Figs. 5 and 6), identifying the characteristic intranuclear
inclusion bodies of CMV; 3 patients developed pseudomem-
branous colitis (Clostridium difﬁcile) showing the typical
presence of the adherent so-called pseudomembranes at
the colonoscopy (Fig. 7), and 1 patient was with superinfec-
tion by Shigella, obtained in fecal cultures and with edema
and multiple small ulcerations in the colon mucosa in the
colonoscopy (Fig. 8). The onset of symptoms began on day
8 onwards. All patients were initially treated with the same
general indications, ﬂuid and electrolyte replacement, etc.,
and then the speciﬁc treatment for each condition, ganci-
clovir 5 mg/kg/b.i.d for CMV, vancomicine 500 mg  IV q.i.d or
metronidazole 500 mg  IV t.i.d for pseudomembranous colitis
and ciproﬂoxacin 500 mg  IV b.i.d for the patient with Shigella
superinfection.Fig. 6 – Photomicrograph of a colonic biopsy obtained by
endoscopy. Viral inclusion in colonic mucosal cells.
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Fig. 7 – Mucosal edema and presence of pseudomembranes
in colonoscopy.
Discussion
The human bone marrow transplantation has become an
accepted treatment for patients with several hematological
disorders.1,13 The marrow is given by intravenous infusion and
within 2–4 weeks the marrow cellularity and peripheral counts
increase as the donor graft becomes functional.
Diagnosis and treatment of the gastrointestinal complica-
tions can be extremely complex, as one must decide whether
a symptom is due to the conditioning regimen toxicity, GVHD,
infection or a combination of causes.12 Diarrhea is a common
and serious symptom of this complications.7,10,14
Chemotherapy toxicity must be suspected when the
patient develops intestinal symptoms from day zero to day
20. Previous studies have shown that diarrhea caused by
cytoreductive therapy has resolved by day 20 in almost all
Fig. 8 – Mucosal edema and ulceration in superinfection by
Shigella.0 1 5;3  5(1):46–52
patients. When chemotherapy is combined with total body
irradiation we observe diffuse mucosal abnormalities within
10 days of transplantation, and necrosis of intestinal crypts,
with atypia of crypt cell nuclei; biopsy specimens taken 16–20
days after transplantation showed evidence of regeneration.
Venocclusive diseases of the liver and pericentral hepatocyte
necrosis have been related to chemoradiation therapy and can
even produce fulminant hepatic failure. The additive or pos-
sible synergistic effect of radiation in inducing organ damage
during allogeneic GVHD is well recognized.5 Thus radiation
has been reported to reduce survival time, induce GVHD at
earlier time, enhance the intensity of GVHD, or increase the
incidence of GVHD.10
Acute GVHD usually starts 4–5 weeks after marrow trans-
plantation, and consists of dermatitis, enteritis, and liver
disease. Patients with intestinal involvement have profuse
diarrhea usually watery with a mucoid appearance, crampy
abdominal pain, nausea, anorexia, and blood in their stools;
the patients may have abdominal pain with sometimes perit-
oneal signs probably for transmural edema and inﬂammation
of the small intestine4; GVHD can involve upper gastrointesti-
nal tract, characterized by the nonspeciﬁc symptomatology of
nausea, vomiting, bloating, and food intolerance15; in colon
the most frequent localization of disease is in the ascending
colon, but all regions of the colon have been reported to be
involved. The basic histopathological feature of acute GVHD,
which occurs in the ﬁrst 100 days posttransplant, is necro-
sis of individual cells in the regenerating compartment of the
mucosa.16 The basic pathology of chronic GVHD is ﬁbrosis of
the submucosa and subserosa which occurs generally after 3
months posttransplant, therefore mucosal biopsy is of limited
usefulness in the diagnosis of chronic GVHD.16
Antimicrobial chemotherapy targeted to intestinal anaer-
obic bacteria in marrow transplant recipients reduces the
severity of acute GVHD and supports the theory that the
intestinal anaerobic bacterial microﬂora plays a signiﬁcant
role in the pathogenesis of acute GVHD after human marrow
transplantation.17,18
Endoscopic examination is usually safe for patients with
GVHD. It can give critical information on clinical deci-
sion making when the histology is discordant with clinical
presentation.19,20 The endoscopic appearance of GVHD ranges
from normal mucosa to erythema, mucosal sloughing, or
patchy erosions.7,10,21,22 Biopsy has been shown to be accurate
in the identiﬁcation of GVHD.7,11
Histopathologic ﬁndings of GVHD are: colonic wall inﬂam-
matory inﬁltrate of mature and activated lymphocytes,
macrophages, and neutrophils.10,23 Crypt dropout and necro-
sis (apoptosis) are the characteristic histological lesions
(“exploding crypt cells”) and are present only in relatively
intact mucosa; when the disease is advanced with total
mucosa denudation the biopsy is less speciﬁc.1,12 GVHD in
biopsy samples can be histologically graded as follows: Grade I:
single cell necrosis and apoptosis; Grade II: evidence of epithe-
lial damage by crypt/glandular abscess, epithelial ﬂattening
or crypt/glandular dilation; Grade III: dropout of one or more
24crypts/glands, and Grade IV: total epithelial denudation.
Radiographic evaluation can show occasional pneumato-
sis in small intestine,25 mucosal and submucosal edema,
and mucosal ulcerations and thickened colonic walls in the
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arium enema, be aware that these ﬁndings can be also
aused by cytomegalovirus enteritis or radiation injury, mak-
ng impossible the differentiation on the basis of radiographic
ndings alone.26 Jones et al.11 used CT scan to evaluate the
xtent of gastrointestinal involvement; their ﬁndings include
all thickening, bowel fold enlargement, bowel dilatation,
uminal narrowing, mesenteric nodes, and increased density
n mesenteric fat compatible with inﬂammation, with scans
btained 16–25 days after initial scans.
The standard treatment of acute GVHD, irrespective of site,
s corticosteroids and/or immunosuppressive agents.4,27 Oper-
tive intervention is rarely therapeutic, but surgery can be
erformed for complications of intestinal graft-versus-host
isease not responding to medical therapy.4,28 Mature surgical
udgment is necessary to avoid unnecessary and very danger-
us operations.
Perianal infections are a rare complication of BMT, these
nfections are polymicrobial, and organisms isolated are
imilar to those seen in the perianal infections of nonimmuno-
uppressed patients.29
The ﬁnding in the stools of fungal elements, parasites,
athogenic bacteria or viruses suggests superinfections com-
licating BMT.
Cytomegalovirus infection has been documented in 40–50%
f patients undergoing BMT.30 Not only immunoglobu-
in and antivirals such as acyclovir are proposed medical
reatments,30 but also surgical treatment has been reported
n complications.31 Diagnosis is made histologically with the
resence of typical or atypical cytomegalovirus inclusions,
ecause the morphologic features are similar with GVHD.32
assive hematochezia secondary to graft-versus-host disease
nd cytomegalovirus infection has been reported.33 Other viral
nfections reported in BMT  patients are herpes simplex virus
nfection. Only six patients with intestinal infection due to
erpes virus (colitis in all of the cases) have been reported in
he literature.34
Cryptosporidia are protozoal parasites that can infect the
astrointestinal tract of man. In immunologically normal sub-
ects the disease is self-limited, resolving in ﬁve to ten days.
ryptosporidium infection has been reported following BMT
s a cause of diarrhea.35 The proposed treatment for this con-
ition includes metronidazole and nitazoxanide which have
een shown to improve symptoms.36
Eosinophilic colitis is a rare inﬂammatory disease charac-
erized by eosinophilic inﬁltration of the colon and peripheral
lood eosinophilia. Eosinophilic colitis has been reported in
ssociation with allogeneic bone marrow transplantation.37
onclusions
s the practice of bone marrow transplant is increasing, it is
lmost certain that a gastroenterologist or colorectal surgeon
hould be faced to this type of colonic complications devel-
ped in consequence. We must know how to identify and treat
hem opportunely with the assistance of a multidisciplinary
eam to offer a good outcome to the patient.
The three principal colonic complications are the
hemotherapy toxicity, GVHD, and superinfection; the
nset of symptoms is important, and could help to suspect
1 5;3  5(1):46–52 51
the type of complication (0–20 day chemotherapy toxicity,
20 and more  GVHD, infection could appear in any time of
transplantation) and plan the type of treatment.
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